1. Home
  2. SLXN vs EVAX Comparison

SLXN vs EVAX Comparison

Compare SLXN & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLXN
  • EVAX
  • Stock Information
  • Founded
  • SLXN 2008
  • EVAX 2008
  • Country
  • SLXN Israel
  • EVAX Denmark
  • Employees
  • SLXN N/A
  • EVAX N/A
  • Industry
  • SLXN
  • EVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SLXN
  • EVAX Health Care
  • Exchange
  • SLXN NYSE
  • EVAX Nasdaq
  • Market Cap
  • SLXN 5.0M
  • EVAX 8.7M
  • IPO Year
  • SLXN N/A
  • EVAX 2021
  • Fundamental
  • Price
  • SLXN $1.26
  • EVAX $2.62
  • Analyst Decision
  • SLXN Strong Buy
  • EVAX Strong Buy
  • Analyst Count
  • SLXN 1
  • EVAX 3
  • Target Price
  • SLXN $9.00
  • EVAX $33.33
  • AVG Volume (30 Days)
  • SLXN 32.1M
  • EVAX 6.9M
  • Earning Date
  • SLXN 02-21-2025
  • EVAX 03-26-2025
  • Dividend Yield
  • SLXN N/A
  • EVAX N/A
  • EPS Growth
  • SLXN N/A
  • EVAX N/A
  • EPS
  • SLXN N/A
  • EVAX N/A
  • Revenue
  • SLXN N/A
  • EVAX $3,295,000.00
  • Revenue This Year
  • SLXN N/A
  • EVAX $4,845.21
  • Revenue Next Year
  • SLXN N/A
  • EVAX $30.30
  • P/E Ratio
  • SLXN N/A
  • EVAX N/A
  • Revenue Growth
  • SLXN N/A
  • EVAX N/A
  • 52 Week Low
  • SLXN $0.21
  • EVAX $2.22
  • 52 Week High
  • SLXN $13.56
  • EVAX $23.70
  • Technical
  • Relative Strength Index (RSI)
  • SLXN N/A
  • EVAX 41.09
  • Support Level
  • SLXN N/A
  • EVAX $2.22
  • Resistance Level
  • SLXN N/A
  • EVAX $4.05
  • Average True Range (ATR)
  • SLXN 0.00
  • EVAX 1.17
  • MACD
  • SLXN 0.00
  • EVAX 0.00
  • Stochastic Oscillator
  • SLXN 0.00
  • EVAX 6.99

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.

About EVAX Evaxion Biotech

Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.

Share on Social Networks: